CSF α-synuclein in relatively early PD has been shown to decrease during 24–36 months of observation in drug-naïve PD patients (Mollenhauer et al., 2019) and during the phase I DATATOP study cohort (Stewart et al., 2014). This evidence concerns the gene SNCA and Parkinson disease.